Overall, our results reveal an unexpected collaboration between cancer cells and Tregs to create an efficient TGF-β-mediated immunosuppressive TME, highlighting that the targeting of Itgβ8 might constitute efficient immunotherapy. The gene discussed is TGFB1; the disease is cancer.